Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Deborah H. Charych(Lawrence Berkeley National Laboratory), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 144